




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61L 29/08, 29/16, 31/10, 31/16	A1	(11) International Publication Number: WO 00/32255 (43) International Publication Date: 8 June 2000 (08.06.00)
(21) International Application Number: PCT/US99/26887 (22) International Filing Date: 12 November 1999 (12.11.99) (30) Priority Data: 09/204,259 3 December 1998 (03.12.98) US (71) Applicant: SCIMED LIFE SYSTEMS, INC. [US/US]; One Scimed Place, Maple Grove, MN 55311-1566 (US). (72) Inventors: KAMATH, Kalpana, R.; 20 Silverhill Lane, Natick, MA 01760 (US). BARRY, James, J.; 35 Jackson Circle, Marlborough, MA 01752 (US). NOTT, Sepideh, H.; 105 Whitman Avenue, Melrose, MA 02176 (US). (74) Agents: BRAINARD, Charles, R. et al.; Kenyon & Kenyon, 1500 K Street, N.W., Suite 700, Washington, DC 20005 (US).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>

(54) Title: POLYMERIC COATINGS WITH CONTROLLED DELIVERY OF ACTIVE AGENTS**(57) Abstract**

Implantable medical device having a structure adapted for introduction into a patient wherein the structure is composed of a base material positioned over the structure. The implantable medical device further includes at least one composite layer of a bioactive agent and a polymer material and at least a barrier layer positioned over the composite layer and being of thickness adequate to provide a controlled release of the bioactive agent. The barrier layer being applied by a lower energy plasma polymerization process which includes placing the device with the at least one composite layer in a plasma chamber and introducing at least one monomer gas.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

POLYMERIC COATINGS FOR CONTROLLED DELIVERY
OF ACTIVE AGENTS

This application is a continuation-in-part of co-
5 pending application Serial No. 09/143,521 filed August
28, 1998, which is incorporated herein in its entirety by
reference thereto.

Field of the Invention

10 The present invention relates to methods and
medical devices for the controlled, localized delivery of
bioactive agents within a body.

Background of the Invention

15 The systemic administration of drug agents,
such as by intravenous means, treats the body as a whole
even though the disease to be treated may be localized.
Thus, it has become common to treat a variety of medical
conditions by introducing an implantable medical device
20 partly or completely into a body cavity such as the
esophagus, trachea, colon, biliary tract, urinary tract,
vascular system or other location within a human or
veterinary patient. For example, many treatments of the
vascular system entail the introduction of a device such
25 as a stent, catheter, balloon, guide wire, cannula or the
like. One of the potential drawbacks to conventional
drug delivery techniques with the use of these devices

being introduced into and manipulated through the vascular system, is that blood vessel walls can be disturbed or injured. Clot formation or thrombosis often results at the injured site, causing stenosis (closure) of the blood vessel.

Another cause of stenosis is vascular disease. Probably the most common disease causing stenosis of blood vessels is atherosclerosis. Atherosclerosis is a condition which commonly affects the coronary arteries, the aorta, the iliofemoral arteries and the carotid arteries.

Many medical devices and therapeutic methods are known for the treatment of atherosclerotic disease. One particular therapy for certain atherosclerotic lesions is percutaneous transluminal coronary angioplasty (PTCA). Another therapy for certain atherosclerotic lesions is percutaneous transluminal angioplasty (PTA). During PTA, a deflated balloon-tipped catheter is inserted in a patient's artery. The tip of the catheter is advanced to the site of atherosclerotic plaque. Inflation of the balloon "cracks" the atherosclerotic plaque and expands the vessel, thereby relieving the stenosis, at least in part.

While PTA presently enjoys wide use, it suffers from two major problems. First, the blood vessel may suffer acute occlusion immediately after or within the initial hour after the dilation procedure. Such occlusion is referred to as "abrupt closure." A second

major problem encountered in PTA is the re-narrowing of an artery after an initially successful angioplasty. This re-narrowing is referred to as "restenosis" and typically occurs within the first six months after angioplasty. Restenosis is believed to arise through the proliferation and migration of cellular components from the arterial wall, as well as through geometric changes in the arterial wall referred to as "remodeling."

A device such as an intravascular stent including stent grafts and covered stents can be a useful adjunct to PTA, particularly in the case of either acute or threatened closure after angioplasty. The stent is placed in the dilated segment of the artery to mechanically prevent abrupt closure and restenosis.

Unfortunately, even when the implantation of the stent is accompanied by aggressive and precise antiplatelet and anticoagulation therapy (typically by systemic administration), the incident of thrombotic vessel closure or other thrombotic complication remains significant, and the prevention of restenosis is not as successful as desired. Furthermore, an undesirable side effect of the systemic antiplatelet and anticoagulation therapy is an increased incidence of bleeding complications, most often at the percutaneous entry site.

Other conditions and diseases are also treatable with stents, catheters, cannulae and other devices inserted into the esophagus, trachea, colon, biliary tract, urinary tract and other locations in the

body, or with orthopedic devices, implants, or replacements, for example. One of the drawbacks of conventional means of drug delivery using such devices is the difficulty in effectively delivering the bioactive agent over a short term (that is, the initial hours and days after insertion of the device) as well as over a long term (the weeks and months after insertion of the device). Another difficulty with the conventional use of stents for drug delivery purposes is providing precise control over the delivery rate of the desired bioactive agents, drug agents or other bioactive material. The term "bioactive agent" is used herein to mean any agent such as a pharmaceutical agent or drug or other material that has a therapeutic effect.

It is desirable to develop devices and methods for reliably delivering suitable amounts of therapeutic agents, drugs or bioactive materials directly into a body portion during or following a medical procedure, so as to treat or prevent such conditions and diseases, for example, to prevent abrupt closure and/or restenosis of a body portion such as a passage, lumen or blood vessel.

In view of the potential drawbacks to conventional drug delivery techniques, there exists a need for a device, method and method of manufacture which enable a controlled localized delivery of active agents, drug agents or bioactive material to target locations within a body.

Summary of the Invention

The foregoing problems are solved and a
5 technical advance is achieved in an illustrative vascular
stent or other implantable medical device that provides a
controlled release of at least one bioactive agent into
the vascular or other system, or other location in the
body, into which the stent or medical device is
10 positioned. In one aspect, the present invention
provides an implantable medical device having a structure
adapted for introduction into a patient, e.g., a stent,
coil, catheter, etc. The implantable medical device of
the invention comprises at least one composite layer of a
15 bioactive agent and a polymer material and at least one
barrier layer positioned over the composite layer or
layers. The barrier layer has a thickness adequate to
provide a controlled release of the bioactive material.
The barrier layer is applied to the medical device by a
20 low energy plasma polymerization process which comprises
placing the composite covered medical device in a plasma
chamber and introducing at least one monomer gas into the
chamber to form at least one barrier layer. In another
embodiment of the invention, the barrier layer comprises
25 at least one bioactive agent.

In another aspect, the present invention
includes a method for the localized delivery of a
bioactive agent to a target location within the body.

The method includes the first steps of providing a medical device having a structure adapted for introduction into a patient wherein the structure is composed of a base material, at least one composite layer of a bioactive agent and a polymer material applied to the base material. At least one barrier layer is positioned over the composite layer and applied to the composite layer by a low energy plasma polymerization process. The barrier layer has a thickness adequate to provide a controlled release of the bioactive material. The plasma polymerization process includes the steps of placing the composite covered device in a plasma chamber and introducing at least one monomer gas into the plasma chamber to form at least one barrier layer on the outer surface of the composite covered device. The method for localized delivery of a bioactive material includes a second step of delivering the implantable medical device to the target location.

Brief Description of the Drawings

Fig. 1 is a cross-sectional view of a first preferred embodiment of the present invention;

Fig. 2 shows side and end views of a stent used in an embodiment of the present invention;

Fig. 3 shows a release profile of the effect of increasing the plasma polymerization time for a siloxane barrier layer in which paclitaxel is released; and

Fig. 4 is a cross-sectional view of a preferred embodiment of the present invention.

Detailed Description

5 The present invention provides implantable medical devices and methods for the controlled, localized delivery of a bioactive agent to target locations within a body. The term "controlled localized delivery" as used herein is defined as a characteristic release rate of the
10 bioactive agent over a desired period of time at a fixed location. The implantable medical devices of the present invention may have a simple construction, provide a minimal cross-sectional profile, and allow for easy and reproducible loading of active agents, drug agents and
15 bioactive material.

 With reference to Fig. 1, an implantable medical device 1 in accordance with the present invention is shown and includes a structure 2 adapted for introduction into a patient. The term "adapted" is used
20 herein to mean that the structure 2 is shaped and sized for such introduction. For clarity, only a portion of structure 2 is shown in Fig. 1.

 By way of example, structure 2 is configured as a stent particularly adapted for insertion into the
25 vascular system of the patient. As known in the art, stents are tubular support structures that are implanted in coronary and peripheral blood vessels or arteries or other non-vascular lumens, blood vessels or other tubular

body lumens. The present invention can thus be used for the dual purpose of localized drug delivery and stent placement, for example. The stent structure may also be used in non-vascular systems and sites such as the esophagus, trachea, colon, biliary ducts, urethra, and ureters, among others. A stent 210 used with the present invention is of any suitable design and is configured in mesh design as shown in Fig. 2.

Referring back to Fig. 1, structure 2 is alternatively configured as any conventional vascular or other medical device, and includes any of a variety of conventional stent or other adjuncts, such as helically wound strands, perforated cylinders or the like. Accordingly, the structure 2 is configured as at least one, or any portion of, a medical device that is adapted for insertion into the body. Examples of such medical devices include catheters, guide wires, balloons, filters (e.g., vena cava filters), stents, stent grafts, vascular grafts, intraluminal paving systems, implants and other devices used in connection with drug-loaded polymer coatings. Such devices are implanted or otherwise utilized in body lumens and organs such as the coronary vasculature, esophagus, trachea, colon, biliary tract, urinary tract, prostate, brain, and the like. Examples of suitable vascular grafts are described in U.S. Pat. Nos. 5,509,931, 5,527,353, and 5,556,426. Vena cava filters such as those described in WO 96/12448 and WO 96/17634 may also be used in the present invention. All

of foregoing documents identified by number are incorporated herein in their entireties.

The grafts, including stent grafts, that are provided with a bioactive agent-polymer composite layer in accordance with the present invention include synthetic vascular grafts that are used for replacement of blood vessels in part or in whole. A typical vascular graft is a synthetic tube with each end thereof sutured to the remaining ends of a blood vessel from which a diseased or otherwise damaged portion has been removed. In a typical stent graft, each end of the synthetic tube portion includes a stent that is affixed to each of the remaining ends of a blood vessel from which a diseased or otherwise damaged portion has been removed. Alternatively in a stent graft, the replacement vessel may be a segment of a vessel removed from another location in the patient, such as a portion of a femoral artery or the like. In the case of a synthetic graft, the graft is typically tubular and may be, e.g., of a woven, knit or velour construction. Preferred base materials for the grafts and covering material for the stent grafts include polyethylene terephthalate and polytetrafluoroethylene. The vascular grafts may be reinforced with, for example, helices, rings, etc. in order to provide uniform strength over the entire surface of the graft tubing. The materials with which such grafts are constructed are biologically compatible materials including, but not limited to, thermoplastic materials such as polyester,

polytetrafluoroethylene (PTFE), silicone and polyurethanes. The preferred materials include polyester fibers and PTFE.

5 Examples of other suitable grafts are described in U.S. Patents Nos. 5,509,931, 5,527,353, and 5,556,426, all of which are herein incorporated by reference. In a most preferred embodiment of the invention, the graft is provided with a composite layer of polymeric material/paclitaxel, and most preferably, the polymeric material
10 is a polyurethane and derivatives thereof. This polymer/paclitaxel composite-coated graft, when positioned at a desired site in the body provides an extended release of paclitaxel to the site.

Turning back to Fig. 1, structure 2 is composed
15 of a base material 3 which is compatible with the intended use of structure 2. The base material 3 is preferably biocompatible.

A variety of conventional materials may be employed as the base material 3. For example, the base
20 material 3 may be either elastic or inelastic. The base material 3 may be either biodegradable or nonbiodegradable. Moreover, some biologic agents have sufficient strength to serve as the base material 3 of structure 2, even if not especially useful in the
25 exemplary coronary stent.

Accordingly, the base material 3 may be formed of stainless steel, tantalum, titanium, nitinol, gold, platinum, inconel, iridium, silver, tungsten, or another

biocompatible metal, or alloys of any of these; carbon or carbon fiber; cellulose acetate, cellulose nitrate; silicone, polyethylene terephthalate, polyurethane, polyamide, polyester, polyorthoester, polyanhydride, polyether sulfone, polycarbonate, polypropylene, high molecular weight polyethylene, polytetrafluoroethylene, or another biocompatible polymeric material, or mixtures or copolymers of these; polylactic acid, polyglycolic acid or copolymers thereof, a polyanhydride, polycaprolactone, polyhydroxybutyrate valerate or another biodegradable polymer, or mixtures or copolymers of these; a protein, an extracellular matrix component, collagen, fibrin or another biologic agent; or a suitable mixture of any of these. Stainless steel and nitinol are particularly useful as base materials when the structure 2 is configured as a vascular stent.

The implantable medical device 1 of the present invention also includes at least one layer 5 formed by a composite of at least one bioactive agent and a biocompatible polymeric or copolymeric material. When multiple polymer-bioactive agent composite layers are used, the layers may contain the same or different bioactive agents and/or the same or different polymers. The combination of bioactive agent and polymer serves as a monolithic matrix depot of the bioactive agent. This depot contributes partially to providing control over the release rate of the bioactive agent from the medical device.

The composite layer(s) are formed from a solution or dispersion (e.g. suspension, emulsion, or semisolid) which is applied to at least a portion of the surface of the base material 3 to form the polymer-bioactive agent composite layer 5. The terms "bioactive agent", "drug agent" and "bioactive material" are used interchangeably herein. The application of polymer-bioactive agent composite 5 onto at least a portion of the base material 3 may be accomplished by a physical method such as, but not limited to, spraying, dipping, painting, electrostatic interaction, physical adsorption or covalent method such as, but not limited to, chemical attachment to the base material 3. The polymer-bioactive agent composite layer 5 is preferably capable of incorporating a substantial amount of bioactive agent, such as, for example, $0.2 \mu\text{g}/\text{mm}^2$ to $20 \mu\text{g}/\text{mm}^2$. The percent of drug in composite layer 5 can be varied from 1% to 50% w/w. The polymer-bioactive agent composite layer 5 is typically applied at a thickness of greater than 1 micron, preferably a thickness of about 5-50 microns and most preferably a thickness of about 5 to 25 microns in order to adjust the bioactive agent dosage. Very thin polymer-bioactive agent composites, e.g., of about 0.2-0.3 microns are also possible. Optionally, multiple layers of polymer-bioactive agent composites may be applied onto the outer surface of the base material (or part(s) thereof) 3 of structure 2. Such multiple layers

can be of the same or different polymer materials and/or bioactive agents.

A vast range of bioactive agents may be incorporated in composite layer 5 as long as the selected bioactive material survives the processes required for application of the bioactive agent-polymerization composite layer onto the device, e.g., plasma polymerization or vapor deposition. Particularly useful in the practice of the present invention are bioactive agents which prevent or ameliorate abrupt closure and restenosis of blood vessels previously opened by stenting surgery or other procedures.

The bioactive agents used in the present invention are selected from a number of therapeutic agents depending on the desired application. For example, these therapeutic agents include anti-inflammatory agents such as dexamethasone, prednisolone, corticosterone, budesonide, estrogen, sulfasalazine, mesalamine, and analogues thereof; antineoplastic/antiproliferative/antimiotic agents such as paclitaxel, 5-fluorouracil, cisplatin, vinblastine, vincristine, epothilones, endostatin, angiostatin, tyrosine kinase inhibitors, and analogues thereof; anesthetic agents such as lidocaine, bupivacaine, ropivacaine, and analogues thereof; anti-coagulants; angiogenic factors and growth factors; and genes encoding for such growth factors and other inhibitory or stimulatory proteins/factors. Also included are nucleic acid compounds such as antisense

oligonucleotides, ribozymes, and genes carried by viral vectors (retro, adeno, adenoassociated, lenti, ebola, herpes simplex, etc.) and non viral systems (plasmid, cationic lipid materials, compacting agents, etc.)

5 The bioactive agents useful in accordance with the present invention may be used singly or in combination. For example, an anti-proliferative agent such as paclitaxel may be used in combination with another drug agent, such as an anticoagulant, anti-inflammatory,
10 antithrombogenic, thrombolytic, nitric oxide-containing polymer, or a vascular cell promoter such as VEGF and FGF, for example.

Paclitaxel is a preferred drug agent for use with the present invention either alone or in combination with
15 another drug agent, as described above. Paclitaxel is a complex alkaloid extracted from the Pacific Yew *Taxus brevifolia* Family (Family Taxaceae) which has been demonstrated to have antiproliferative activity. As used herein, paclitaxel includes the alkaloid and any
20 pharmacologically active derivative or analog thereof. Thus paclitaxel includes naturally occurring forms and derivatives thereof and synthetic and semi-synthetic forms thereof. TAXOL® (Bristol- Meyers Squibb Company) is a commercially available form of paclitaxel. These
25 and other compounds are added to the polymer material using similar methods and routinely tested as set forth in the specification. Any modifications are routinely made by one skilled in the art.

The biocompatible polymeric material used to form the bioactive agent-polymer composite layer(s) may include any polymeric material capable of forming a solidified composite layer in the presence of the bioactive material. The polymeric material of the present invention is hydrophilic or hydrophobic, and is, for example, polycarboxylic acids, cellulosic polymers, including cellulose acetate and cellulose nitrate, gelatin, polyvinylpyrrolidone, cross-linked polyvinylpyrrolidone, polyanhydrides including maleic anhydride polymers, polyamides, polyvinyl alcohols, polyolefins, copolymers of vinyl monomers such as EVA, polyvinyl ethers, polyvinyl aromatics, polyethylene oxides, glycosaminoglycans, polysaccharides, polyesters including polyethylene terephthalate, polyacrylamides, polyethers, polyether sulfone, polycarbonate, polyalkylenes including polypropylene, polyethylene and high molecular weight polyethylene, halogenated polyalkylenes including polytetrafluoroethylene, polyurethanes, polyorthoesters, proteins, polypeptides, silicones, siloxane polymers, polylactic acid, polyglycolic acid, polycaprolactone, polyhydroxybutyrate valerate and blends and copolymers thereof as well as other biodegradable, bioabsorbable and biostable polymers and copolymers. Coatings from polymer dispersions such as polyurethane dispersions (BAYHDROL®, etc.) and acrylic latex dispersions are also within the scope of the present invention. The polymer may be a protein polymer,

fibrin, collagen and derivatives thereof, polysaccharides such as celluloses, starches, dextrans, alginates and derivatives of these polysaccharides, an extracellular matrix component, hyaluronic acid, or another biologic agent or a suitable mixture of any of these, for example. Composite layer 5 can include of a single polymer or copolymer. It may also include copolymers or physical blends of any of the materials indicated above. In one embodiment of the invention, the preferred polymer is polyacrylic acid, available as HYDROPLUS® (Boston Scientific Corporation, Natick, Mass.), and described in U.S. Patent No. 5,091,205, the disclosure of which is hereby incorporated herein by reference. U.S. Patent No. 5,091,205 describes medical devices coated with one or more polyisocyanates such that the devices become instantly lubricious when exposed to body fluids. In a most preferred embodiment of the invention, the polymer is a polyurethane and derivatives thereof.

The use of the bioactive agent-polymer composite layer 5 in the present invention has the added advantage in that this layer or multilayers allow for enhanced adhesion of the mixture to the base material 3 as opposed to the prior art methods of first applying a polymer followed by a drug coating. The bioactive agent-polymer composite layer 5 also provides for an effective way of adjusting the amount of the bioactive agent placed on the base material 3. This is accomplished by adjusting the bioactive agent/polymer ratio and/or

thickness of the bioactive agent-polymer composite layer. Also, composite layer 5 provides a co-compliant surface for a subsequent barrier layer and aids in maintaining the mechanical integrity of the barrier layer during the expansion of the medical device. The bioactive agent-polymer composite also has the added benefit of providing a blood compatible surface to the medical device. Thus, the biocompatible polymer material acts as an intermediary between the vascular walls or the blood stream and the implantable medical device 1.

The release profile of the drug from the bioactive agent-polymer composite layer 5 is determined by many factors including the drug solubility, the amount of the drug applied, the drug-to-polymer ratio in composite layer 5 and the thickness and porosity of the composite layer. The release profile is also regulated by the presence of an outer barrier layer which is formed by a vapor deposition process or a low energy plasma polymerization process.

Still with reference to Fig. 1, implantable medical device 1 of the present invention also includes at least one barrier layer 20 positioned over the bioactive agent-polymer composite layer(s) 5. One purpose of this barrier layer or layers is to provide further controlled release of the bioactive material when device 1 is positioned in the vascular system or other body lumen of a patient. The thickness of the barrier layer 6 is chosen so as to provide such control. Also,

the barrier layer 20 protects the drug from the routine handling process and physiologic milieu until the drug reaches the target site. In an alternative embodiment of the invention, the barrier layer(s) may contain an
5 additional bioactive agent which may be the same or different from the bioactive agent of the bioactive agent-polymer composite layer(s).

The barrier layer 20 is a polymer or copolymer layer deposited on the outer surface of the bioactive
10 agent-polymer composite layer 5 by a vapor deposition process or a low energy plasma polymerization process. Low-energy plasma polymerization is performed by exposing the composite coated implantable medical device to a monomer gas at the inception of the plasma polymerization
15 process. The bioactive agent-polymer composite-coated device is placed in a plasma chamber or other similar device and exposed to a monomer gas such as, for example, silicone-based monomers such as cyclic or acyclic siloxanes, silanes, silylimidazoles; fluorine-based
20 monomers such as hydrofluorocarbons; aliphatic or aromatic hydrocarbons; acrylic monomers; N-vinyl pyrrolidone; ethylene oxide or combinations thereof. The monomer gas may have functional groups to allow covalent attachment of appropriate drugs by anchoring to these
25 functional groups. Polymer blends, copolymers, or interpenetrating networks can be deposited in addition to homopolymer deposition, by simultaneous or subsequent introduction of two or more monomer gases. When

introduced as a mixture, the ratio of the monomer gases could be adjusted to obtain desired properties. An energy source such as a radio frequency energy source is used to produce the low energy generating process.

5 Alternatively, the barrier layer can be applied by the vapor deposition process. Examples of polymers that can be deposited in such a manner are parylene or polyamides. For deposition of parylene using this process, the monomer vapor of p-xylylene formed by high
10 temperature pyrolysis of its dimer form, is condensed at temperatures of 50 C or lower on the surface of composite layer (5) to form the barrier layer polymer.

 Low-energy plasma generates active species in a circulating monomer gas, a polymer is formed and is
15 subsequently deposited on the outer surface of the previously-coated device. The plasma may also generate active species on the device to be coated along with the monomer gas. This leads to plasma grafting in addition to plasma polymerization. Properties of the low-energy
20 plasma polymerization barrier layer (i.e., the thickness and/or cross-linking density of the formed polymer) are controlled, for example, by the monomer flow rate, pressure and power of the plasma supplied, reaction time, and combinations thereof in a manner such that the
25 properties of the bioactive agent(s) are not negatively effected.

 The use of low-energy plasma polymerization provides for elimination of thermal effects of typical

polymerization methods because the low-energy process occurs at room temperature. Also, since the monomer is introduced in a gaseous form, in the plasma chamber, no solvents are necessary for the application to the
5 bioactive agent-composite layer. Furthermore, since the time frame used for the low-energy process is small, the possibility of any adverse effects to the bioactive agent is minimal.

Another purpose of barrier layer 20 is to
10 provide protection of the bioactive agent-polymer composite layer 5 from damage that may occur, e.g., from handling of the device, such as during maneuvering of the device through the body until it is placed at the desired target site. This could be achieved in one or more
15 different way.

For example, the plasma polymerization process allows covalent anchoring of the barrier layer 20 to the polymer matrix in the composite layer 5. The formation of covalent bonds between the composite layer 5 and the
20 barrier layer 20 subsequently offers a stronger adhesion of the barrier layer 20 and hence an enhanced protection of the drug depot in the composite layer 5 in comparison to that offered by other methods described in the prior art.

25 Also, in the case of a hydrophobic barrier layer, the diffusion of water from the physiologic environment is restricted, thus limiting contact of the bioactive agent with the eluting environment.

Additionally, the barrier layer formed by plasma polymerization is cross-linked in nature as opposed to barrier layers formed by other approaches described in the prior art. The degree of cross-linking can be varied by varying the plasma polymerization process parameters, such as the power. An added endurance could be obtained by increasing the cross-linking density and hence a more rigid barrier layer, while lowering the cross-linking density provides a more flexible barrier layer.

The at least one barrier layer 20 of the present invention is preferably less than 5000 Å thick and optimally about 50-2000 Å thick.

As noted above, the release profile of the bioactive material from the medical device is determined by many factors including the solubility of the bioactive agent in the barrier layer, porosity of both the composite and barrier layers, cross-linking density and thickness of the barrier layer, and hence resistance to the transport of the bioactive agent through the barrier layer.

Fig. 3 shows the effects of increasing the plasma polymerization time on the release rate of the bioactive agent. In Figure 3, a siloxane barrier layer is applied onto a paclitaxel-polyurethane composite layer of a stent by a low energy plasma polymerization process including polyurethane and derivatives thereof including polycarbonate based, polyurea based, polyether based, and

polyester based derivatives. Also included are Inter-Penetrating Network (INP)s such as siliconized polyurethane. The paclitaxel-polyurethane-coated stent is exposed to gaseous monomers of

5 tetramethylcyclotetrasiloxane, which are then polymerized by low energy plasma polymerization onto the surface of the paclitaxel-polyurethane coating. As can be seen from Figure 3, it is possible to achieve progressively slower release profiles of paclitaxel by increasing the plasma
10 polymerization times, for example, from 6 seconds to 10 seconds to 20 seconds. An increase in polymerization time results in the formation of a thicker siloxane barrier layer, which in turn causes a sustaining effect on the paclitaxel release rate. Thus, the release profile
15 of paclitaxel or other bioactive agent is precisely controlled by varying the time of the low energy plasma polymerization process.

Furthermore, modifications of any one or more of the basic plasma parameters such as the plasma polymerization
20 time, the monomer flow rate, the pressure, and the energy applied offers the possibility of either changing the thickness and/or cross-linking density of the formed polymer. Both of these properties can, in turn, provide a means to control drug release by offering an enhanced
25 resistance to the drug elution from the composite layer. Also, since the low energy plasma polymerization process utilizes gaseous phase for polymer application, coating selective areas on the coated stent may easily be

achieved (by masking appropriate areas), which is difficult to achieve in a solution phase coating application.

In an alternative embodiment, a bioactive material(s) is incorporated into or on the outer surface of the barrier layer. For example, a second bioactive material is introduced into the barrier layer 20 by any suitable method. Fig.4 shows a stent having an outer coating of bioactive agent, such as heparin, which is applied to barrier layer 20 to produce layer 25. The outer bioactive material, which may be the same or different from the bioactive agent of the bioactive agent-polymer composite layer, is placed in solution and applied to the barrier layer 20 by any suitable means, including dipping the coated medical device into the drug solution or by applying the solution onto the layer 20 such as by spraying. In the former method, the amount of bioactive material loading is controlled by regulating the time the barrier layer is exposed to the drug solution or dispersion, the extent of polymer cross-linking, the concentration of the drug in the solution or dispersion and/or the amount of barrier layer applied to the medical device.

The barrier layer with the second bioactive drug may have a similar composition or may differ physically or chemically from the first barrier layer. The nature of the second barrier layer would be dictated by the physicochemical properties of the second drug to

be incorporated on the outer surface. For example, for the incorporation of hydrophilic agent, such as heparin, the second barrier layer may include a hydrophilic/hydrophobic polymer network formed by plasma polymerization. The hydrophilic component may be provided by plasma polymerization of monomers such as, N-vinyl pyrrolidone or ethylene oxide, while the hydrophobic component is provided by siloxane-based polymers. The incorporation and release of the hydrophilic bioactive agent is thus facilitated due to its higher affinity for the hydrophilic polymer. In such a situation, the drug release occurs by dissolution/erosion of the hydrophilic polymeric component followed by diffusion through the hydrophobic counterpart.

In the event that the bioactive material used in the layer 5 is the same as the bioactive material in layer 20, the bioactive material of layer 5 provides an initial bolus loading dose required to reach the therapeutic window, which is further maintained by the bioactive agent-polymer composite layer 5.

In the event that the bioactive material of layer 5 is different from the bioactive material used with layer 20, the bioactive material in layer 20 provides a combination of biological effects achieved by either a synergistic or independent bioactivity of the two bioactive materials. For example, a combination of paclitaxel with corticosteroids or nitric oxide or nitric

oxide donors as the bioactive material provides a synergistic effect. An example of a combination of bioactive agents that provide independent bioactivity useful for the treatment of restenosis is paclitaxel and heparin. In another example, heparin, heparin binding growth factors and nitric oxide donor are incorporated within the barrier layer 20 to obtain multiple benefits of non-thrombogenicity and enhanced endothelialization. In an additional embodiment, layer 20 includes proteins or biological moieties to further modulate the drug release from layer 20.

When implanted, a substantial amount of the bioactive material contained in the bioactive agent-polymer composite layer 5 of the medical device is diffused into the affected area over an extended period of time and in a controlled manner.

The present invention provides a device, method of treatment and method of manufacture which controls the localized delivery of active agents, drug agents or bioactive material to target locations within a body. Although the present invention has been described with respect to several exemplary embodiments, there are many other variations of the above-described embodiments which will be apparent to those skilled in the art, even when elements have not explicitly been designated as exemplary. It is understood that these modifications are within the teaching of the present invention, which is to be limited only to the claims appended hereto.

What is claimed is:

1 1. An implantable medical device comprising:
2 a structure adapted for introduction into a
3 patient, wherein the structure comprises a base material;
4 at least one composite layer comprising at
5 least one bioactive agent and polymer material applied to
6 at least a portion of the outer surface of said base
7 material; and
8 at least one barrier layer positioned over the
9 composite layer, said barrier layer having a thickness
10 adequate to provide controlled release of the at least
11 one bioactive agent;
12 wherein said barrier layer is formed in situ by
13 a low energy plasma polymerization process of a monomer
14 gas.

1 2. The implantable device of claim 1, wherein said
2 polymer material comprises a polymer selected from the
3 group consisting of polyurethane, polycarboxylic acids,
4 polyorthoesters, polyvinylpyrrolidone, maleic anhydride
5 polymers, polyamides, polyvinyl alcohols, polyethylene
6 oxides, glycosaminoglycans, proteins, polypeptides,
7 silicones, polysaccharides, polyesters, polyacrylamides,
8 polyethers, copolymers of vinyl monomers, and mixtures
9 and copolymers thereof.

1 3. The device of claim 1, wherein said at least
2 one bioactive agent is paclitaxel.

1 4. The device of claim 1, wherein said at least
2 one composite layer is formed by dissolution, dispersion,
3 absorption, or adsorption of said at least one bioactive
4 agent and polymer material.

1 5. The device of claim 1, wherein said at least
2 one composite layer forms a matrix depot of the bioactive
3 agent.

1 6. The device of claim 1, wherein the thickness of
2 said at least one barrier layer is less than 5000 Å.

1 7. The device of claim 6, wherein the thickness of
2 said at least one barrier layer is about 50 to 2000 Å.

1 8. The device of claim 1, wherein the medical
2 device is a device selected from the group consisting of
3 a catheter, wire guide, cannula, stent graft, covered
4 stent, vascular or other graft, cardiac pacemaker lead or
5 lead tip; an angioplasty device or portion thereof; and
6 any portion thereof.

1 9. The device of claim 1, wherein the base
2 material of the structure comprises at least one of metal
3 or polymer.

1 10. The device of claim 1, wherein said monomer gas
2 is selected from the group consisting of a cyclic or
3 acyclic siloxane silicon-based monomers, silane silicon-
4 based monomers, silylimidazoles silicon-based monomers,
5 hydrofluorocarbon-based monomers; aliphatic or aromatic
6 hydrocarbon-based monomer; acrylic monomer; and
7 combinations thereof.

1 11. The device of claim 1, further comprising a
2 drug layer over said barrier layer.

1 12. The device of claim 6, wherein said drug layer
2 includes heparin.

1 13. A method for the localized delivery of a drug
2 agent to a target location within a body, comprising the
3 steps of:

4 A) providing an implantable medical device
5 which comprises a coated structure adapted for
6 introduction into a patient, the structure comprising:

7 (a) a base material;

8 (b) at least one composite layer
9 comprising at least one bioactive agent and a polymer
10 material applied to at least a portion of the outer
11 surface of said base material;

12 B) forming at least one barrier layer
13 comprising a polymer over the composite layer of said
14 medical device, wherein said at least one barrier layer

15 has a thickness adequate to provide a controlled release
16 of the at least one bioactive agent, wherein said barrier
17 layer is applied by a low energy plasma polymerization
18 process which comprises:

- 19 (i) placing said coated structure in a
20 chamber;
21 (ii) introducing at least one monomer gas
22 into said chamber; and
23 (iii) exposing the gas to a low energy
24 source, whereby the monomer gas forms a barrier layer on
25 the outer surface of the medical device; and
26 C) delivering said implantable medical device
27 to said target location.

1 14. The method of claim 13, further comprising the
2 step of introducing additional bioactive agent into said
3 at least one barrier layer by a dipping process.

1 15. A method according to claim 13, wherein the low
2 energy source is low energy radio frequency.




FIG. 1

210




FIG. 2

**Taxol release from 35% Taxol/Chronoflex coated (Exp. 33)
and 35% Taxol/PUR with Siloxane top coat (in sec)**




FIG. 3




FIG. 4

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 99/26887

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61L29/08 A61L29/16 A61L31/10 A61L31/16

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61L A61F A61K A61M

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 36784 A (COOK INC) 27 August 1998 (1998-08-27) page 5, line 26 -page 6, line 24 claims 1-3,8,9 -----	1-5,8-15
A	WO 97 38801 A (TIMMONS RICHARD B ;UNIV TEXAS (US); WANG JENN HANN (US)) 23 October 1997 (1997-10-23) page 14, line 11 -page 16, line 26 claims -----	1,2,4-15
A	WO 95 13313 A (SURFACE ENG TECH) 18 May 1995 (1995-05-18) page 1, line 19 -page 2, line 2 page 18, line 22 - line 31 claims 1-5,11-19,31,32,36,37 -----	1,2,4-15

☐ Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

7 April 2000

Date of mailing of the international search report

20/04/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Thornton, S

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/26887

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: —
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 13-15 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the implant.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 13-15 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the implant.

Continuation of Box I.1

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by surgery

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/26887

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9836784 A	27-08-1998	AU 6663298 A EP 0968013 A	09-09-1998 05-01-2000
WO 9738801 A	23-10-1997	US 5876753 A AU 2735597 A CA 2253408 A CN 1221359 A EP 0904157 A	02-03-1999 07-11-1997 23-10-1997 30-06-1999 31-03-1999
WO 9513313 A	18-05-1995	US 5463010 A EP 0740680 A JP 9505104 T	31-10-1995 06-11-1996 20-05-1997



CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 June 2000 (08.06.2000)


PCT

(10) International Publication Number
WO 00/32255 A1

- (51) International Patent Classification⁷: A61L 29/08, 29/16, 31/10, 31/16
- (21) International Application Number: PCT/US99/26887
- (22) International Filing Date: 12 November 1999 (12.11.1999)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 09/204,259 3 December 1998 (03.12.1998) US
- (71) Applicant: SCIMED LIFE SYSTEMS, INC. [US/US];
One Scimed Place, Maple Grove, MN 55311-1566 (US).
- (72) Inventors: KAMATH, Kalpana, R.; 20 Silverhill Lane, Natick, MA 01760 (US). BARRY, James, J.; 35 Jackson Circle, Marlborough, MA 10752 (US). NOTT, Sepideh, H.; 105 Whitman Avenue, Melrose, MA 02176 (US).
- (74) Agents: BRAINARD, Charles, R. et al.; Kenyon & Kenyon, 1500 K Street, N.W., Suite 700, Washington, DC 20005 (US).
- (81) Designated States (*national*): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

[Continued on next page]

(54) Title: POLYMERIC COATINGS WITH CONTROLLED DELIVERY OF ACTIVE AGENTS



(57) Abstract: Implantable medical device having a structure adapted for introduction into a patient wherein the structure is composed of a base material positioned over the structure. The implantable medical device further includes at least one composite layer of a bioactive agent and a polymer material and at least a barrier layer positioned over the composite layer and being of thickness adequate to provide a controlled release of the bioactive agent. The barrier layer being applied by a lower energy plasma polymerization process which includes placing the device with the at least one composite layer in a plasma chamber and introducing at least one monomer gas.

WO 00/32255 A1



(84) **Designated States** (*regional*): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

-- With international search report.

(48) **Date of publication of this corrected version:**

29 March 2001

(15) **Information about Correction:**

see PCT Gazette No. 13/2001 of 29 March 2001, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

POLYMERIC COATINGS FOR CONTROLLED DELIVERY
OF ACTIVE AGENTS

5 This application is a continuation-in-part of co-
pending application Serial No. 09/143,521 filed August
28, 1998, which is incorporated herein in its entirety by
reference thereto.

Field of the Invention

10 The present invention relates to methods and
medical devices for the controlled, localized delivery of
bioactive agents within a body.

Background of the Invention

15 The systemic administration of drug agents,
such as by intravenous means, treats the body as a whole
even though the disease to be treated may be localized.
Thus, it has become common to treat a variety of medical
conditions by introducing an implantable medical device
20 partly or completely into a body cavity such as the
esophagus, trachea, colon, biliary tract, urinary tract,
vascular system or other location within a human or
veterinary patient. For example, many treatments of the
vascular system entail the introduction of a device such
25 as a stent, catheter, balloon, guide wire, cannula or the
like. One of the potential drawbacks to conventional
drug delivery techniques with the use of these devices

being introduced into and manipulated through the vascular system, is that blood vessel walls can be disturbed or injured. Clot formation or thrombosis often results at the injured site, causing stenosis (closure)
5 of the blood vessel.

Another cause of stenosis is vascular disease. Probably the most common disease causing stenosis of blood vessels is atherosclerosis. Atherosclerosis is a condition which commonly affects the coronary arteries,
10 the aorta, the iliofemoral arteries and the carotid arteries.

Many medical devices and therapeutic methods are known for the treatment of atherosclerotic disease. One particular therapy for certain atherosclerotic
15 lesions is percutaneous transluminal coronary angioplasty (PTCA). Another therapy for certain atherosclerotic lesions is percutaneous transluminal angioplasty (PTA). During PTA, a deflated balloon-tipped catheter is inserted in a patient's artery. The tip of the catheter
20 is advanced to the site of atherosclerotic plaque. Inflation of the balloon "cracks" the atherosclerotic plaque and expands the vessel, thereby relieving the stenosis, at least in part.

While PTA presently enjoys wide use, it suffers
25 from two major problems. First, the blood vessel may suffer acute occlusion immediately after or within the initial hour after the dilation procedure. Such occlusion is referred to as "abrupt closure." A second

major problem encountered in PTA is the re-narrowing of an artery after an initially successful angioplasty.

This re-narrowing is referred to as "restenosis" and typically occurs within the first six months after

5 angioplasty. Restenosis is believed to arise through the proliferation and migration of cellular components from the arterial wall, as well as through geometric changes in the arterial wall referred to as "remodeling."

A device such as an intravascular stent
10 including stent grafts and covered stents can be a useful adjunct to PTA, particularly in the case of either acute or threatened closure after angioplasty. The stent is placed in the dilated segment of the artery to mechanically prevent abrupt closure and restenosis.

15 Unfortunately, even when the implantation of the stent is accompanied by aggressive and precise antiplatelet and anticoagulation therapy (typically by systemic administration), the incident of thrombotic vessel closure or other thrombotic complication remains
20 significant, and the prevention of restenosis is not as successful as desired. Furthermore, an undesirable side effect of the systemic antiplatelet and anticoagulation therapy is an increased incidence of bleeding complications, most often at the percutaneous entry site.

25 Other conditions and diseases are also treatable with stents, catheters, cannulae and other devices inserted into the esophagus, trachea, colon, biliary tract, urinary tract and other locations in the

body, or with orthopedic devices, implants, or
replacements, for example. One of the drawbacks of
conventional means of drug delivery using such devices is
the difficulty in effectively delivering the bioactive
5 agent over a short term (that is, the initial hours and
days after insertion of the device) as well as over a
long term (the weeks and months after insertion of the
device). Another difficulty with the conventional use of
stents for drug delivery purposes is providing precise
10 control over the delivery rate of the desired bioactive
agents, drug agents or other bioactive material. The term
"bioactive agent" is used herein to mean any agent such
as a pharmaceutical agent or drug or other material that
has a therapeutic effect.

15 It is desirable to develop devices and methods
for reliably delivering suitable amounts of therapeutic
agents, drugs or bioactive materials directly into a body
portion during or following a medical procedure, so as to
treat or prevent such conditions and diseases, for
20 example, to prevent abrupt closure and/or restenosis of a
body portion such as a passage, lumen or blood vessel.

In view of the potential drawbacks to
conventional drug delivery techniques, there exists a
need for a device, method and method of manufacture which
25 enable a controlled localized delivery of active agents,
drug agents or bioactive material to target locations
within a body.

Summary of the Invention

The foregoing problems are solved and a technical advance is achieved in an illustrative vascular stent or other implantable medical device that provides a controlled release of at least one bioactive agent into the vascular or other system, or other location in the body, into which the stent or medical device is positioned. In one aspect, the present invention provides an implantable medical device having a structure adapted for introduction into a patient, e.g., a stent, coil, catheter, etc. The implantable medical device of the invention comprises at least one composite layer of a bioactive agent and a polymer material and at least one barrier layer positioned over the composite layer or layers. The barrier layer has a thickness adequate to provide a controlled release of the bioactive material. The barrier layer is applied to the medical device by a low energy plasma polymerization process which comprises placing the composite covered medical device in a plasma chamber and introducing at least one monomer gas into the chamber to form at least one barrier layer. In another embodiment of the invention, the barrier layer comprises at least one bioactive agent.

In another aspect, the present invention includes a method for the localized delivery of a bioactive agent to a target location within the body.

The method includes the first steps of providing a medical device having a structure adapted for introduction into a patient wherein the structure is composed of a base material, at least one composite layer of a bioactive agent and a polymer material applied to the base material. At least one barrier layer is positioned over the composite layer and applied to the composite layer by a low energy plasma polymerization process. The barrier layer has a thickness adequate to provide a controlled release of the bioactive material. The plasma polymerization process includes the steps of placing the composite covered device in a plasma chamber and introducing at least one monomer gas into the plasma chamber to form at least one barrier layer on the outer surface of the composite covered device. The method for localized delivery of a bioactive material includes a second step of delivering the implantable medical device to the target location.

Brief Description of the Drawings

Fig. 1 is a cross-sectional view of a first preferred embodiment of the present invention;

Fig. 2 shows side and end views of a stent used in an embodiment of the present invention;

Fig. 3 shows a release profile of the effect of increasing the plasma polymerization time for a siloxane barrier layer in which paclitaxel is released; and

Fig. 4 is a cross-sectional view of a preferred embodiment of the present invention.

Detailed Description

5 The present invention provides implantable medical devices and methods for the controlled, localized delivery of a bioactive agent to target locations within a body. The term "controlled localized delivery" as used herein is defined as a characteristic release rate of the
10 bioactive agent over a desired period of time at a fixed location. The implantable medical devices of the present invention may have a simple construction, provide a minimal cross-sectional profile, and allow for easy and reproducible loading of active agents, drug agents and
15 bioactive material.

 With reference to Fig. 1, an implantable medical device 1 in accordance with the present invention is shown and includes a structure 2 adapted for introduction into a patient. The term "adapted" is used
20 herein to mean that the structure 2 is shaped and sized for such introduction. For clarity, only a portion of structure 2 is shown in Fig. 1.

 By way of example, structure 2 is configured as a stent particularly adapted for insertion into the
25 vascular system of the patient. As known in the art, stents are tubular support structures that are implanted in coronary and peripheral blood vessels or arteries or other non-vascular lumens, blood vessels or other tubular

body lumens. The present invention can thus be used for the dual purpose of localized drug delivery and stent placement, for example. The stent structure may also be used in non-vascular systems and sites such as the
5 esophagus, trachea, colon, biliary ducts, urethra, and ureters, among others. A stent 210 used with the present invention is of any suitable design and is configured in mesh design as shown in Fig. 2.

Referring back to Fig. 1, structure 2 is
10 alternatively configured as any conventional vascular or other medical device, and includes any of a variety of conventional stent or other adjuncts, such as helically wound strands, perforated cylinders or the like. Accordingly, the structure 2 is configured as at least
15 one, or any portion of, a medical device that is adapted for insertion into the body. Examples of such medical devices include catheters, guide wires, balloons, filters (e.g., vena cava filters), stents, stent grafts, vascular grafts, intraluminal paving systems, implants and other
20 devices used in connection with drug-loaded polymer coatings. Such devices are implanted or otherwise utilized in body lumens and organs such as the coronary vasculature, esophagus, trachea, colon, biliary tract, urinary tract, prostate, brain, and the like. Examples
25 of suitable vascular grafts are described in U.S. Pat. Nos. 5,509,931, 5,527,353, and 5,556,426. Vena cava filters such as those described in WO 96/12448 and WO 96/17634 may also be used in the present invention. All

of foregoing documents identified by number are incorporated herein in their entireties.

The grafts, including stent grafts, that are provided with a bioactive agent-polymer composite layer in accordance with the present invention include synthetic vascular grafts that are used for replacement of blood vessels in part or in whole. A typical vascular graft is a synthetic tube with each end thereof sutured to the remaining ends of a blood vessel from which a diseased or otherwise damaged portion has been removed. In a typical stent graft, each end of the synthetic tube portion includes a stent that is affixed to each of the remaining ends of a blood vessel from which a diseased or otherwise damaged portion has been removed. Alternatively in a stent graft, the replacement vessel may be a segment of a vessel removed from another location in the patient, such as a portion of a femoral artery or the like. In the case of a synthetic graft, the graft is typically tubular and may be, e.g., of a woven, knit or velour construction. Preferred base materials for the grafts and covering material for the stent grafts include polyethylene terephthalate and polytetrafluoroethylene. The vascular grafts may be reinforced with, for example, helices, rings, etc. in order to provide uniform strength over the entire surface of the graft tubing. The materials with which such grafts are constructed are biologically compatible materials including, but not limited to, thermoplastic materials such as polyester,

polytetrafluoroethylene (PTFE), silicone and polyurethanes. The preferred materials include polyester fibers and PTFE.

Examples of other suitable grafts are described in U.S. Patents Nos. 5,509,931, 5,527,353, and 5,556,426, all of which are herein incorporated by reference. In a most preferred embodiment of the invention, the graft is provided with a composite layer of polymeric material/paclitaxel, and most preferably, the polymeric material is a polyurethane and derivatives thereof. This polymer/paclitaxel composite-coated graft, when positioned at a desired site in the body provides an extended release of paclitaxel to the site.

Turning back to Fig. 1, structure 2 is composed of a base material 3 which is compatible with the intended use of structure 2. The base material 3 is preferably biocompatible.

A variety of conventional materials may be employed as the base material 3. For example, the base material 3 may be either elastic or inelastic. The base material 3 may be either biodegradable or nonbiodegradable. Moreover, some biologic agents have sufficient strength to serve as the base material 3 of structure 2, even if not especially useful in the exemplary coronary stent.

Accordingly, the base material 3 may be formed of stainless steel, tantalum, titanium, nitinol, gold, platinum, inconel, iridium, silver, tungsten, or another

biocompatible metal, or alloys of any of these; carbon or carbon fiber; cellulose acetate, cellulose nitrate; silicone, polyethylene terephthalate, polyurethane, polyamide, polyester, polyorthoester, polyanhydride, polyether sulfone, polycarbonate, polypropylene, high molecular weight polyethylene, polytetrafluoroethylene, or another biocompatible polymeric material, or mixtures or copolymers of these; polylactic acid, polyglycolic acid or copolymers thereof, a polyanhydride, polycaprolactone, polyhydroxybutyrate valerate or another biodegradable polymer, or mixtures or copolymers of these; a protein, an extracellular matrix component, collagen, fibrin or another biologic agent; or a suitable mixture of any of these. Stainless steel and nitinol are particularly useful as base materials when the structure 2 is configured as a vascular stent.

The implantable medical device 1 of the present invention also includes at least one layer 5 formed by a composite of at least one bioactive agent and a biocompatible polymeric or copolymeric material. When multiple polymer-bioactive agent composite layers are used, the layers may contain the same or different bioactive agents and/or the same or different polymers. The combination of bioactive agent and polymer serves as a monolithic matrix depot of the bioactive agent. This depot contributes partially to providing control over the release rate of the bioactive agent from the medical device.

The composite layer(s) are formed from a solution or dispersion (e.g. suspension, emulsion, or semisolid) which is applied to at least a portion of the surface of the base material 3 to form the polymer-bioactive agent composite layer 5. The terms "bioactive agent", "drug agent" and "bioactive material" are used interchangeably herein. The application of polymer-bioactive agent composite 5 onto at least a portion of the base material 3 may be accomplished by a physical method such as, but not limited to, spraying, dipping, painting, electrostatic interaction, physical adsorption or covalent method such as, but not limited to, chemical attachment to the base material 3. The polymer-bioactive agent composite layer 5 is preferably capable of incorporating a substantial amount of bioactive agent, such as, for example, $0.2 \mu\text{g}/\text{mm}^2$ to $20 \mu\text{g}/\text{mm}^2$. The percent of drug in composite layer 5 can be varied from 1% to 50% w/w. The polymer-bioactive agent composite layer 5 is typically applied at a thickness of greater than 1 micron, preferably a thickness of about 5-50 microns and most preferably a thickness of about 5 to 25 microns in order to adjust the bioactive agent dosage. Very thin polymer-bioactive agent composites, e.g., of about 0.2-0.3 microns are also possible. Optionally, multiple layers of polymer-bioactive agent composites may be applied onto the outer surface of the base material (or part(s) thereof) 3 of structure 2. Such multiple layers

can be of the same or different polymer materials and/or bioactive agents.

A vast range of bioactive agents may be incorporated in composite layer 5 as long as the selected bioactive material survives the processes required for application of the bioactive agent-polymerization composite layer onto the device, e.g., plasma polymerization or vapor deposition. Particularly useful in the practice of the present invention are bioactive agents which prevent or ameliorate abrupt closure and restenosis of blood vessels previously opened by stenting surgery or other procedures.

The bioactive agents used in the present invention are selected from a number of therapeutic agents depending on the desired application. For example, these therapeutic agents include anti-inflammatory agents such as dexamethasone, prednisolone, corticosterone, budesonide, estrogen, sulfasalazine, mesalamine, and analogues thereof; antineoplastic/antiproliferative/antimicrobial agents such as paclitaxel, 5-fluorouracil, cisplatin, vinblastine, vincristine, epothilones, endostatin, angiostatin, tyrosine kinase inhibitors, and analogues thereof; anesthetic agents such as lidocaine, bupivacaine, ropivacaine, and analogues thereof; anti-coagulants; angiogenic factors and growth factors; and genes encoding for such growth factors and other inhibitory or stimulatory proteins/factors. Also included are nucleic acid compounds such as antisense

oligonucleotides, ribozymes, and genes carried by viral vectors (retro, adeno, adenoassociated, lenti, ebola, herpes simplex, etc.) and non viral systems (plasmid, cationic lipid materials, compacting agents, etc.)

5 The bioactive agents useful in accordance with the present invention may be used singly or in combination. For example, an anti-proliferative agent such as paclitaxel may be used in combination with another drug agent, such as an anticoagulant, anti-inflammatory,
10 antithrombogenic, thrombolytic, nitric oxide-containing polymer, or a vascular cell promoter such as VEGF and FGF, for example.

 Paclitaxel is a preferred drug agent for use with the present invention either alone or in combination with
15 another drug agent, as described above. Paclitaxel is a complex alkaloid extracted from the Pacific Yew *Taxus brevifolia* Family (Family Taxaceae) which has been demonstrated to have antiproliferative activity. As used herein, paclitaxel includes the alkaloid and any
20 pharmacologically active derivative or analog thereof. Thus paclitaxel includes naturally occurring forms and derivatives thereof and synthetic and semi-synthetic forms thereof. TAXOL® (Bristol- Meyers Squibb Company) is a commercially available form of paclitaxel. These
25 and other compounds are added to the polymer material using similar methods and routinely tested as set forth in the specification. Any modifications are routinely made by one skilled in the art.

The biocompatible polymeric material used to form the bioactive agent-polymer composite layer(s) may include any polymeric material capable of forming a solidified composite layer in the presence of the bioactive material. The polymeric material of the present invention is hydrophilic or hydrophobic, and is, for example, polycarboxylic acids, cellulosic polymers, including cellulose acetate and cellulose nitrate, gelatin, polyvinylpyrrolidone, cross-linked polyvinylpyrrolidone, polyanhydrides including maleic anhydride polymers, polyamides, polyvinyl alcohols, polyolefins, copolymers of vinyl monomers such as EVA, polyvinyl ethers, polyvinyl aromatics, polyethylene oxides, glycosaminoglycans, polysaccharides, polyesters including polyethylene terephthalate, polyacrylamides, polyethers, polyether sulfone, polycarbonate, polyalkylenes including polypropylene, polyethylene and high molecular weight polyethylene, halogenated polyalkylenes including polytetrafluoroethylene, polyurethanes, polyorthoesters, proteins, polypeptides, silicones, siloxane polymers, polylactic acid, polyglycolic acid, polycaprolactone, polyhydroxybutyrate valerate and blends and copolymers thereof as well as other biodegradable, bioabsorbable and biostable polymers and copolymers. Coatings from polymer dispersions such as polyurethane dispersions (BAYHDROL®, etc.) and acrylic latex dispersions are also within the scope of the present invention. The polymer may be a protein polymer,

fibrin, collagen and derivatives thereof, polysaccharides such as celluloses, starches, dextrans, alginates and derivatives of these polysaccharides, an extracellular matrix component, hyaluronic acid, or another biologic agent or a suitable mixture of any of these, for example. Composite layer 5 can include of a single polymer or copolymer. It may also include copolymers or physical blends of any of the materials indicated above. In one embodiment of the invention, the preferred polymer is polyacrylic acid, available as HYDROPLUS® (Boston Scientific Corporation, Natick, Mass.), and described in U.S. Patent No. 5,091,205, the disclosure of which is hereby incorporated herein by reference. U.S. Patent No. 5,091,205 describes medical devices coated with one or more polyisocyanates such that the devices become instantly lubricious when exposed to body fluids. In a most preferred embodiment of the invention, the polymer is a polyurethane and derivatives thereof.

The use of the bioactive agent-polymer composite layer 5 in the present invention has the added advantage in that this layer or multilayers allow for enhanced adhesion of the mixture to the base material 3 as opposed to the prior art methods of first applying a polymer followed by a drug coating. The bioactive agent-polymer composite layer 5 also provides for an effective way of adjusting the amount of the bioactive agent placed on the base material 3. This is accomplished by adjusting the bioactive agent/polymer ratio and/or

thickness of the bioactive agent-polymer composite layer. Also, composite layer 5 provides a co-compliant surface for a subsequent barrier layer and aids in maintaining the mechanical integrity of the barrier layer during the expansion of the medical device. The bioactive agent-polymer composite also has the added benefit of providing a blood compatible surface to the medical device. Thus, the biocompatible polymer material acts as an intermediary between the vascular walls or the blood stream and the implantable medical device 1.

The release profile of the drug from the bioactive agent-polymer composite layer 5 is determined by many factors including the drug solubility, the amount of the drug applied, the drug-to-polymer ratio in composite layer 5 and the thickness and porosity of the composite layer. The release profile is also regulated by the presence of an outer barrier layer which is formed by a vapor deposition process or a low energy plasma polymerization process.

Still with reference to Fig. 1, implantable medical device 1 of the present invention also includes at least one barrier layer 20 positioned over the bioactive agent-polymer composite layer(s) 5. One purpose of this barrier layer or layers is to provide further controlled release of the bioactive material when device 1 is positioned in the vascular system or other body lumen of a patient. The thickness of the barrier layer 6 is chosen so as to provide such control. Also,

the barrier layer 20 protects the drug from the routine handling process and physiologic milieu until the drug reaches the target site. In an alternative embodiment of the invention, the barrier layer(s) may contain an additional bioactive agent which may be the same or different from the bioactive agent of the bioactive agent-polymer composite layer(s).

The barrier layer 20 is a polymer or copolymer layer deposited on the outer surface of the bioactive agent-polymer composite layer 5 by a vapor deposition process or a low energy plasma polymerization process. Low-energy plasma polymerization is performed by exposing the composite coated implantable medical device to a monomer gas at the inception of the plasma polymerization process. The bioactive agent-polymer composite-coated device is placed in a plasma chamber or other similar device and exposed to a monomer gas such as, for example, silicone-based monomers such as cyclic or acyclic siloxanes, silanes, silylimidazoles; fluorine-based monomers such as hydrofluorocarbons; aliphatic or aromatic hydrocarbons; acrylic monomers; N-vinyl pyrrolidone; ethylene oxide or combinations thereof. The monomer gas may have functional groups to allow covalent attachment of appropriate drugs by anchoring to these functional groups. Polymer blends, copolymers, or interpenetrating networks can be deposited in addition to homopolymer deposition, by simultaneous or subsequent introduction of two or more monomer gases. When

introduced as a mixture, the ratio of the monomer gases could be adjusted to obtain desired properties. An energy source such as a radio frequency energy source is used to produce the low energy generating process.

5 Alternatively, the barrier layer can be applied by the vapor deposition process. Examples of polymers that can be deposited in such a manner are parylene or polyamides. For deposition of parylene using this process, the monomer vapor of p-xylylene formed by high
10 temperature pyrolysis of its dimer form, is condensed at temperatures of 50 C or lower on the surface of composite layer (5) to form the barrier layer polymer.

 Low-energy plasma generates active species in a circulating monomer gas, a polymer is formed and is
15 subsequently deposited on the outer surface of the previously-coated device. The plasma may also generate active species on the device to be coated along with the monomer gas. This leads to plasma grafting in addition to plasma polymerization. Properties of the low-energy
20 plasma polymerization barrier layer (i.e., the thickness and/or cross-linking density of the formed polymer) are controlled, for example, by the monomer flow rate, pressure and power of the plasma supplied, reaction time, and combinations thereof in a manner such that the
25 properties of the bioactive agent(s) are not negatively effected.

 The use of low-energy plasma polymerization provides for elimination of thermal effects of typical

polymerization methods because the low-energy process occurs at room temperature. Also, since the monomer is introduced in a gaseous form, in the plasma chamber, no solvents are necessary for the application to the
5 bioactive agent-composite layer. Furthermore, since the time frame used for the low-energy process is small, the possibility of any adverse effects to the bioactive agent is minimal.

Another purpose of barrier layer 20 is to
10 provide protection of the bioactive agent-polymer composite layer 5 from damage that may occur, e.g., from handling of the device, such as during maneuvering of the device through the body until it is placed at the desired target site. This could be achieved in one or more
15 different way.

For example, the plasma polymerization process allows covalent anchoring of the barrier layer 20 to the polymer matrix in the composite layer 5. The formation of covalent bonds between the composite layer 5 and the
20 barrier layer 20 subsequently offers a stronger adhesion of the barrier layer 20 and hence an enhanced protection of the drug depot in the composite layer 5 in comparison to that offered by other methods described in the prior art.

25 Also, in the case of a hydrophobic barrier layer, the diffusion of water from the physiologic environment is restricted, thus limiting contact of the bioactive agent with the eluting environment.

Additionally, the barrier layer formed by plasma polymerization is cross-linked in nature as opposed to barrier layers formed by other approaches described in the prior art. The degree of cross-linking can be varied by varying the plasma polymerization process parameters, such as the power. An added endurance could be obtained by increasing the cross-linking density and hence a more rigid barrier layer, while lowering the cross-linking density provides a more flexible barrier layer.

The at least one barrier layer 20 of the present invention is preferably less than 5000 Å thick and optimally about 50-2000 Å thick.

As noted above, the release profile of the bioactive material from the medical device is determined by many factors including the solubility of the bioactive agent in the barrier layer, porosity of both the composite and barrier layers, cross-linking density and thickness of the barrier layer, and hence resistance to the transport of the bioactive agent through the barrier layer.

Fig. 3 shows the effects of increasing the plasma polymerization time on the release rate of the bioactive agent. In Figure 3, a siloxane barrier layer is applied onto a paclitaxel-polyurethane composite layer of a stent by a low energy plasma polymerization process including polyurethane and derivatives thereof including polycarbonate based, polyurea based, polyether based, and

polyester based derivatives. Also included are Inter-Penetrating Network (INP)s such as siliconized polyurethane. The paclitaxel-polyurethane-coated stent is exposed to gaseous monomers of

5 tetramethylcyclotetrasiloxane, which are then polymerized by low energy plasma polymerization onto the surface of the paclitaxel-polyurethane coating. As can be seen from Figure 3, it is possible to achieve progressively slower release profiles of paclitaxel by increasing the plasma
10 polymerization times, for example, from 6 seconds to 10 seconds to 20 seconds. An increase in polymerization time results in the formation of a thicker siloxane barrier layer, which in turn causes a sustaining effect on the paclitaxel release rate. Thus, the release profile
15 of paclitaxel or other bioactive agent is precisely controlled by varying the time of the low energy plasma polymerization process.

Furthermore, modifications of any one or more of the basic plasma parameters such as the plasma polymerization
20 time, the monomer flow rate, the pressure, and the energy applied offers the possibility of either changing the thickness and/or cross-linking density of the formed polymer. Both of these properties can, in turn, provide a means to control drug release by offering an enhanced
25 resistance to the drug elution from the composite layer. Also, since the low energy plasma polymerization process utilizes gaseous phase for polymer application, coating selective areas on the coated stent may easily be

achieved (by masking appropriate areas), which is difficult to achieve in a solution phase coating application.

In an alternative embodiment, a bioactive material(s) is incorporated into or on the outer surface of the barrier layer. For example, a second bioactive material is introduced into the barrier layer 20 by any suitable method. Fig.4 shows a stent having an outer coating of bioactive agent, such as heparin, which is applied to barrier layer 20 to produce layer 25. The outer bioactive material, which may be the same or different from the bioactive agent of the bioactive agent-polymer composite layer, is placed in solution and applied to the barrier layer 20 by any suitable means, including dipping the coated medical device into the drug solution or by applying the solution onto the layer 20 such as by spraying. In the former method, the amount of bioactive material loading is controlled by regulating the time the barrier layer is exposed to the drug solution or dispersion, the extent of polymer cross-linking, the concentration of the drug in the solution or dispersion and/or the amount of barrier layer applied to the medical device.

The barrier layer with the second bioactive drug may have a similar composition or may differ physically or chemically from the first barrier layer. The nature of the second barrier layer would be dictated by the physicochemical properties of the second drug to

be incorporated on the outer surface. For example, for the incorporation of hydrophilic agent, such as heparin, the second barrier layer may include a hydrophilic/hydrophobic polymer network formed by plasma polymerization. The hydrophilic component may be provided by plasma polymerization of monomers such as, N-vinyl pyrrolidone or ethylene oxide, while the hydrophobic component is provided by siloxane-based polymers. The incorporation and release of the hydrophilic bioactive agent is thus facilitated due to its higher affinity for the hydrophilic polymer. In such a situation, the drug release occurs by dissolution/erosion of the hydrophilic polymeric component followed by diffusion through the hydrophobic counterpart.

In the event that the bioactive material used in the layer 5 is the same as the bioactive material in layer 20, the bioactive material of layer 5 provides an initial bolus loading dose required to reach the therapeutic window, which is further maintained by the bioactive agent-polymer composite layer 5.

In the event that the bioactive material of layer 5 is different from the bioactive material used with layer 20, the bioactive material in layer 20 provides a combination of biological effects achieved by either a synergistic or independent bioactivity of the two bioactive materials. For example, a combination of paclitaxel with corticosteroids or nitric oxide or nitric

oxide donors as the bioactive material provides a synergistic effect. An example of a combination of bioactive agents that provide independent bioactivity useful for the treatment of restenosis is paclitaxel and heparin. In another example, heparin, heparin binding growth factors and nitric oxide donor are incorporated within the barrier layer 20 to obtain multiple benefits of non-thrombogenicity and enhanced endothelialization. In an additional embodiment, layer 20 includes proteins or biological moieties to further modulate the drug release from layer 20.

When implanted, a substantial amount of the bioactive material contained in the bioactive agent-polymer composite layer 5 of the medical device is diffused into the affected area over an extended period of time and in a controlled manner.

The present invention provides a device, method of treatment and method of manufacture which controls the localized delivery of active agents, drug agents or bioactive material to target locations within a body. Although the present invention has been described with respect to several exemplary embodiments, there are many other variations of the above-described embodiments which will be apparent to those skilled in the art, even when elements have not explicitly been designated as exemplary. It is understood that these modifications are within the teaching of the present invention, which is to be limited only to the claims appended hereto.

What is claimed is:

1 1. An implantable medical device comprising:
2 a structure adapted for introduction into a
3 patient, wherein the structure comprises a base material;
4 at least one composite layer comprising at
5 least one bioactive agent and polymer material applied to
6 at least a portion of the outer surface of said base
7 material; and
8 at least one barrier layer positioned over the
9 composite layer, said barrier layer having a thickness
10 adequate to provide controlled release of the at least
11 one bioactive agent;
12 wherein said barrier layer is formed in situ by
13 a low energy plasma polymerization process of a monomer
14 gas.

1 2. The implantable device of claim 1, wherein said
2 polymer material comprises a polymer selected from the
3 group consisting of polyurethane, polycarboxylic acids,
4 polyorthoesters, polyvinylpyrrolidone, maleic anhydride
5 polymers, polyamides, polyvinyl alcohols, polyethylene
6 oxides, glycosaminoglycans, proteins, polypeptides,
7 silicones, polysaccharides, polyesters, polyacrylamides,
8 polyethers, copolymers of vinyl monomers, and mixtures
9 and copolymers thereof.

1 3. The device of claim 1, wherein said at least
2 one bioactive agent is paclitaxel.

1 4. The device of claim 1, wherein said at least
2 one composite layer is formed by dissolution, dispersion,
3 absorption, or adsorption of said at least one bioactive
4 agent and polymer material.

1 5. The device of claim 1, wherein said at least
2 one composite layer forms a matrix depot of the bioactive
3 agent.

1 6. The device of claim 1, wherein the thickness of
2 said at least one barrier layer is less than 5000 Å.

1 7. The device of claim 6, wherein the thickness of
2 said at least one barrier layer is about 50 to 2000 Å.

1 8. The device of claim 1, wherein the medical
2 device is a device selected from the group consisting of
3 a catheter, wire guide, cannula, stent graft, covered
4 stent, vascular or other graft, cardiac pacemaker lead or
5 lead tip; an angioplasty device or portion thereof; and
6 any portion thereof.

1 9. The device of claim 1, wherein the base
2 material of the structure comprises at least one of metal
3 or polymer.

1 10. The device of claim 1, wherein said monomer gas
2 is selected from the group consisting of a cyclic or
3 acyclic siloxane silicon-based monomers, silane silicon-
4 based monomers, silylimidazoles silicon-based monomers,
5 hydrofluorocarbon-based monomers; aliphatic or aromatic
6 hydrocarbon-based monomer; acrylic monomer; and
7 combinations thereof.

1 11. The device of claim 1, further comprising a
2 drug layer over said barrier layer.

1 12. The device of claim 6, wherein said drug layer
2 includes heparin.

1 13. A method for the localized delivery of a drug
2 agent to a target location within a body, comprising the
3 steps of:

4 A) providing an implantable medical device
5 which comprises a coated structure adapted for
6 introduction into a patient, the structure comprising:

7 (a) a base material;

8 (b) at least one composite layer
9 comprising at least one bioactive agent and a polymer
10 material applied to at least a portion of the outer
11 surface of said base material;

12 B) forming at least one barrier layer
13 comprising a polymer over the composite layer of said
14 medical device, wherein said at least one barrier layer

15 has a thickness adequate to provide a controlled release
16 of the at least one bioactive agent, wherein said barrier
17 layer is applied by a low energy plasma polymerization
18 process which comprises:

19 (i) placing said coated structure in a
20 chamber;

21 (ii) introducing at least one monomer gas
22 into said chamber; and

23 (iii) exposing the gas to a low energy
24 source, whereby the monomer gas forms a barrier layer on
25 the outer surface of the medical device; and

26 C) delivering said implantable medical device
27 to said target location.

1 14. The method of claim 13, further comprising the
2 step of introducing additional bioactive agent into said
3 at least one barrier layer by a dipping process.

1 15. A method according to claim 13, wherein the low
2 energy source is low energy radio frequency.

1/4




FIG. 1

2/4




FIG. 2B




FIG. 2A

3/4




FIG.3

4/4




FIG. 4

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 99/26887

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61L29/08 A61L29/16 A61L31/10 A61L31/16

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61L A61F A61K A61M

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 36784 A (COOK INC) 27 August 1998 (1998-08-27) page 5, line 26 -page 6, line 24 claims 1-3,8,9	1-5,8-15
A	WO 97 38801 A (TIMMONS RICHARD B ;UNIV TEXAS (US); WANG JENN HANN (US)) 23 October 1997 (1997-10-23) page 14, line 11 -page 16, line 26 claims	1,2,4-15
A	WO 95 13313 A (SURFACE ENG TECH) 18 May 1995 (1995-05-18) page 1, line 19 -page 2, line 2 page 18, line 22 - line 31 claims 1-5,11-19,31,32,36,37	1,2,4-15



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

7 April 2000

Date of mailing of the international search report

20/04/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Thornton, S

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/26887

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 13-15 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the implant.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 13-15 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the implant.

Continuation of Box I.1

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by surgery

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/26887

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9836784 A	27-08-1998	AU 6663298 A EP 0968013 A	09-09-1998 05-01-2000
WO 9738801 A	23-10-1997	US 5876753 A AU 2735597 A CA 2253408 A CN 1221359 A EP 0904157 A	02-03-1999 07-11-1997 23-10-1997 30-06-1999 31-03-1999
WO 9513313 A	18-05-1995	US 5463010 A EP 0740680 A JP 9505104 T	31-10-1995 06-11-1996 20-05-1997






FIG. 1

210




FIG. 2

Taxol release from 35% Taxol/Chronoflex coated (Exp. 33)
and 35% Taxol/PUR with Siloxane top coat (in sec)




FIG. 3




FIG. 4